Skip to main content
. 2022 Oct 31;12(2):156–170. doi: 10.1159/000527759

Fig. 2.

Fig. 2

Association between baseline MIG (CXCL9) levels and early PD treated with atezolizumab plus bevacizumab. a Comparison of baseline serum CXCL9 levels between patients with and without early PD, or an objective response to atezolizumab and bevacizumab. b Best cut-off value of CXCL9 levels for predicting early PD following atezolizumab and bevacizumab treatment. The best cut-off value was determined based on the receiver operating characteristic curve obtained by maximizing the Youden index. The cut-off baseline CXCL9 level for predicting early PD after atezolizumab and bevacizumab was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). Rate of early PD in patients with ≥333 pg/mL and <333 pg/mL baseline CXCL9 following atezolizumab plus bevacizumab treatment. c Kaplan-Meier estimates of PFS stratified by <333 pg/mL, the baseline CXCL9. Median PFS in patients with ≥333 pg/mL and <333 pg/mL baseline CXCL9 is 126 days and 227 days, respectively (HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084).